Cover Image

Camrelizumab Combined with FOLFOX4 Regimen as First-Line Therapy for Advanced Hepatocellular Carcinomas: A Sub-Cohort of a Multicenter Phase Ib/II Study

Hui Li,1,* Shukui Qin,1,* Ying Liu,2 Zhendong Chen,3 Zhenggang Ren,4 Jianping Xiong,5 Zhiqiang Meng,6 Xiao Zhang,7 Linna Wang,7 Xiaojing Zhang,7 Jianjun Zou7 1Department of Medical Oncology Center, Bayi Affiliated Hospital, Nanjing University of Chinese Medicine, Nanjing, People’s Republic...

Full description

Saved in:

Bibliographic Details
Main Authors:	Li H (Author), Qin S (Author), Liu Y (Author), Chen Z (Author), Ren Z (Author), Xiong J (Author), Meng Z (Author), Zhang X (Author), Wang L (Author), Zou J (Author)
Format:	Book
Published:	Dove Medical Press, 2021-05-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Immune-Related Colitis Induced by Camrelizumab: A Case Report
by: Cheng S, et al.
Published: (2023)

Comprehensive Treatment of Trans-Arterial Chemoembolization Plus Lenvatinib Followed by Camrelizumab for Advanced Hepatocellular Carcinoma Patients
by: Juanfang Liu, et al.
Published: (2021)

Cost-effectiveness analysis of camrelizumab plus chemotherapy as first-line treatment for advanced squamous NSCLC in China
by: Taihang Shao, et al.
Published: (2022)

Akkermansia Muciniphila Potentiates the Antitumor Efficacy of FOLFOX in Colon Cancer
by: Xiaoying Hou, et al.
Published: (2021)

Massive Hepatocellular Carcinoma with Situs Inversus Totalis Achieved a Complete Response Following Camrelizumab Plus Apatinib and Combined with Two-Stage Hepatectomy: A Case Report
by: Wu Y, et al.
Published: (2023)

Efficacy and safety of FLOT regimen vs DCF, FOLFOX, and ECF regimens as perioperative chemotherapy treatments for resectable gastric cancer patients; a report from the middle east
by: Pegah Farrokhi, et al.
Published: (2022)

In vivo solid phase microextraction for therapeutic monitoring and pharmacometabolomic fingerprinting of lung during in vivo lung perfusion of FOLFOX
by: Nikita Looby, et al.
Published: (2023)

Efficacy and Prognostic Factors of Regorafenib in the Treatment of BCLC Stage C Hepatocellular Carcinoma After Failure of the First-Line Therapy
by: Xu B, et al.
Published: (2023)

Comparison of hepatic arterial infusion chemotherapy with mFOLFOX vs. first-line systemic chemotherapy in patients with unresectable intrahepatic cholangiocarcinoma
by: Zhenyun Yang, et al.
Published: (2023)

Economic Evaluation of First-Line Camrelizumab for Advanced Non-small-cell Lung Cancer in China
by: Guiyuan Xiang, et al.
Published: (2021)

Effects on Cardiac Biomarkers in Colorectal Cancer Patients Treated With FOLFOX
by: Nusrat Bano, et al.
Published: (2024)

Exploring the impact of MiR-92a-3p on FOLFOX chemoresistance biomarker genes in colon cancer cell lines
by: Paula I. Escalante, et al.
Published: (2024)

Predicting Outcome in Combination Treatment of TACE and Camrelizumab for Advanced Hepatocellular carcinoma: Tumor Hypervascularity and Reactive Cutaneous Capillary Endothelial Proliferation
by: Yin L, et al.
Published: (2022)

Cost-Effectiveness Analysis of Camrelizumab Versus Chemotherapy as Second-Line Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma
by: Hongfu Cai, et al.
Published: (2021)

Apatinib in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Phase II, Open-Label, Single-Arm, Prospective Study
by: Ma X, et al.
Published: (2020)

Clinical Efficacy and Safety of an Immune Checkpoint Inhibitor in Combination with Regorafenib Therapy as Second-Line Regimen for Patients with Unresectable Hepatocellular Carcinoma
by: Li J, et al.
Published: (2023)

Composition of fecal microbiota in low-set rectal cancer patients treated with FOLFOX
by: Jing Li, et al.
Published: (2020)

Cost-effectiveness analysis of tislelizumab vs. camrelizumab for the treatment of second-line locally advanced or metastatic esophageal squamous cell carcinoma
by: Pingyu Chen, et al.
Published: (2024)

A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in Australia
by: Lickliter JD, et al.
Published: (2020)

Contraceptive efficacy and safety of estradiol valerate/dienogest in a healthy female population: a multicenter, open-label, uncontrolled Phase III study
by: Yu Q, et al.
Published: (2018)

Cyclosporine A (0.05%) Ophthalmic Gel in the Treatment of Dry Eye Disease: A Multicenter, Randomized, Double-Masked, Phase III, COSMO Trial
by: Peng W, et al.
Published: (2022)

miRNAs and lncRNAs as Predictive Biomarkers of Response to FOLFOX Therapy in Colorectal Cancer
by: Kha Wai Hon, et al.
Published: (2018)

Commentary: Intermittent Fasting and Akkermansia Muciniphila Potentiate the Antitumor Efficacy of FOLFOX in Colon Cancer
by: Junhong Su, et al.
Published: (2022)

The Safety and Efficacy of Camrelizumab and Its Combination With Apatinib in Various Solid Cancers
by: Kunlun Wang, et al.
Published: (2020)

A Systemic Inflammation Response Score for Prognostic Prediction in Hepatocellular Carcinoma Patients After Hepatectomy
by: Zhang D, et al.
Published: (2022)

Combining Preoperative and Postoperative Inflammatory Indicators Can Better Predict the Recurrence of Hepatocellular Carcinoma After Partial Hepatectomy
by: Wu M, et al.
Published: (2021)

A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Novel Intravenous Formulation of Meloxicam (QP001) in Healthy Chinese Subjects
by: Ma J, et al.
Published: (2023)

A Correlation Evaluation Between the Peripheral Blood Index and the Prognosis of Advanced Esophageal Squamous Cell Carcinoma Patients Treated with Camrelizumab
by: Shang H, et al.
Published: (2024)

Polyploidy Spectrum Correlates with Immunophenotype and Shapes Hepatocellular Carcinoma Recurrence Following Liver Transplantation
by: Zhang L, et al.
Published: (2022)

Cost-effectiveness analysis of camrelizumab plus paclitaxel and carboplatin versus sintilimab plus gemcitabine and cisplatin or carboplatin for the first-line treatment of local advanced or metastatic squamous NSCLC in Chinese mainland
by: Xiaoting Liu, et al.
Published: (2024)

Cost-effectiveness analysis of zolbetuximab plus mFOLFOX6 as the first-line treatment for CLDN18.2-positive, HER2-negative advanced gastric or Gastroesophageal Adenocarcinoma
by: Yufan Huang, et al.
Published: (2023)

An open‐label, nonrandomized, phase Ib feasibility study of cusatuzumab in patients with nasopharyngeal carcinoma
by: Astrid De Meulenaere, et al.
Published: (2021)

The Neutrophil-to-Albumin Ratio (NAR): A Novel Index in Relation to Clinical Symptoms, Quality of Life, and Psychological Status in Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)
by: Huang X, et al.
Published: (2024)

Cost-Effectiveness of Domestic PD-1 Inhibitor Camrelizumab Combined With Chemotherapy in the First-Line Treatment of Advanced Nonsquamous Non-Small-Cell Lung Cancer in China
by: Liu Qiao, et al.
Published: (2021)

Clinical Significance of Prior Ramucirumab Use on the Effectiveness of Nivolumab as the Third-Line Regimen in Gastric Cancer: A Multicenter Retrospective Study
by: Yuka Obayashi, et al.
Published: (2024)

Therapeutic effects of tyroserleutide on lung metastasis of human hepatocellular carcinoma SK-HEP-1 and its mechanism affecting ICAM-1 and MMP-2 and -9
by: Che X, et al.
Published: (2018)

Severe proteinuria during the administration of bevacizumab plus mFOLFOX6 in a colorectal cancer patient after kidney transplantation: a case report
by: Ren Onodera, et al.
Published: (2020)

Therapeutic Effects of Tyroserleutide on Lung Metastasis of Human Hepatocellular Carcinoma SK-HEP-1 and Its Mechanism Affecting ICAM-1 and MMP-2 and -9 [Retraction]
by: Che X, et al.
Published: (2023)

Combining nanoparticle albumin-bound paclitaxel with camrelizumab in advanced soft tissue sarcoma: activity, safety, and future perspectives
by: Zhichao Tian, et al.
Published: (2024)

Phase Line Attila The Amphibious Campaign for Cyprus, 1974
by: Erickson, Edward J.
Published: (2020)